Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Shmuel Yaccoby. (2010) Osteoblastogenesis and tumor growth in myeloma. Leukemia & Lymphoma 51:2, pages 213-220.
Read now
Read now
Kanoko Kohmura, Yoshitaka Miyakawa, Kaori Kameyama, Masahiro Kizaki & Yasuo Ikeda. (2004) Granulocyte Colony Stimulating Factor-Producing Multiple Myeloma Associated with Neutrophilia. Leukemia & Lymphoma 45:7, pages 1475-1479.
Read now
Read now
Articles from other publishers (26)
Dominika Bębnowska, Rafał Hrynkiewicz, Ewelina Grywalska, Marcin Pasiarski, Barbara Sosnowska-Pasiarska, Iwona Smarz-Widelska, Stanisław Góźdź, Jacek Roliński & Paulina Niedźwiedzka-Rystwej. (2021) Immunological Prognostic Factors in Multiple Myeloma. International Journal of Molecular Sciences 22:7, pages 3587.
Crossref
Crossref
Dinuka M. De Silva, Arpita Roy & Donald P. Bottaro. 2018. Extracellular Targeting of Cell Signaling in Cancer. Extracellular Targeting of Cell Signaling in Cancer
155
198
.
Anna Li Santi, Anna Gorrasi, Mariaevelina Alfieri, Nunzia Montuori & Pia Ragno. (2018) A novel oncogenic role for urokinase receptor in leukemia cells: molecular sponge for oncosuppressor microRNAs. Oncotarget 9:45, pages 27823-27834.
Crossref
Crossref
Marjorie Boissinot, Mathias Vilaine & Sylvie Hermouet. (2014) The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?. Cancers 6:3, pages 1631-1669.
Crossref
Crossref
Jérôme Moreaux, Caroline Bret, Karène Mahtouk, Anne-Catherine Sprynski, Dirk Hose & Bernard Klein. 2013. Advances in Biology and Therapy of Multiple Myeloma. Advances in Biology and Therapy of Multiple Myeloma
65
84
.
Meng-Meng Cao, Wang-Xiang Xu, Chang-Yan Li, Chuan-Zeng Cao, Zhi-Dong Wang, Jia-Wei Yao, Miao Yu, Yi-Qun Zhan, Xiao-Hui Wang, Liu-Jun Tang, Hui Chen, Wei Li, Chang-Hui Ge & Xiao-Ming Yang. (2011) Hepassocin regulates cell proliferation of the human hepatic cells L02 and hepatocarcinoma cells through different mechanisms. Journal of Cellular Biochemistry 112:10, pages 2882-2890.
Crossref
Crossref
Joseph P. Ritchie, Vishnu C. Ramani, Yongsheng Ren, Annamaria Naggi, Giangiacomo Torri, Benito Casu, Sergio Penco, Claudio Pisano, Paolo Carminati, Monica Tortoreto, Franco Zunino, Israel Vlodavsky, Ralph D. Sanderson & Yang Yang. (2011) SST0001, a Chemically Modified Heparin, Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase/Syndecan-1 Axis. Clinical Cancer Research 17:6, pages 1382-1393.
Crossref
Crossref
Vishnu C. Ramani, Yang Yang, Yongsheng Ren, Li Nan & Ralph D. Sanderson. (2011) Heparanase Plays a Dual Role in Driving Hepatocyte Growth Factor (HGF) Signaling by Enhancing HGF Expression and Activity. Journal of Biological Chemistry 286:8, pages 6490-6499.
Crossref
Crossref
Miguel Lemaire, Sarah Deleu, Elke De Bruyne, Els Van Valckenborgh, Eline Menu & Karin Vanderkerken. 2011.
19
42
.
Yanran Cao, Tim Luetkens, Sebastian Kobold, York Hildebrandt, Maja Gordic, Nesrine Lajmi, Sabrina Meyer, Katrin Bartels, Axel R. Zander, Carsten Bokemeyer, Nicolaus Kröger & Djordje Atanackovic. (2010) The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. Experimental Hematology 38:10, pages 860-867.
Crossref
Crossref
Garima SinghalMoganty R. Rajeswari. (2010)
Molecular Aspects of the Interaction of Hoechst-33258 with GC-Rich Promoter Region of
c-met
. DNA and Cell Biology 29:2, pages 91-100.
Crossref
Crossref
Benedetta Accordi, Serena Pillozzi, Marta Campo Dell'Orto, Giovanni Cazzaniga, Annarosa Arcangeli, Geertruy te Kronnie & Giuseppe Basso. (2007) Hepatocyte Growth Factor Receptor c-MET Is Associated with FAS and When Activated Enhances Drug-induced Apoptosis in Pediatric B Acute Lymphoblastic Leukemia with TEL-AML1 Translocation. Journal of Biological Chemistry 282:40, pages 29384-29393.
Crossref
Crossref
Ismail Oguz Kara, Berksoy Sahin, Ramazan Gunesacar & Cagatay Unsal. (2006) Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-α in bone marrow and peripheral blood of patients with multiple myeloma. Advances in Therapy 23:4, pages 635-645.
Crossref
Crossref
Michael A. Morgan & Christoph W. M. Reuter. (2006) Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias. Annals of Hematology 85:3, pages 139-163.
Crossref
Crossref
Jérôme MoreauxFriedrich W. CremerThierry RemeMarc RaabKarene MahtoukPhiline KaukelVeronique PantescoJohn De VosEric JourdanAnna JauchEric LegouffeMarion MoosGenevieve FiolHartmut GoldschmidtJean François RossiDirk HoseBernard Klein. (2005) The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106:3, pages 1021-1030.
Crossref
Crossref
Shaji KumarThomas E. WitzigMichael TimmJessica HaugLinda WellikTeresa K. KimlingerPhilip R. GreippS. Vincent Rajkumar. (2004) Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 104:4, pages 1159-1165.
Crossref
Crossref
Kerstin Schag, Susanne M. Schmidt, Martin R. Müller, Toni Weinschenk, Silke Appel, Markus M. Weck, Frank Grünebach, Stefan Stevanovic, Hans-Georg Rammensee & Peter Brossart. (2004) Identification of C-Met Oncogene as a Broadly Expressed Tumor-Associated Antigen Recognized by Cytotoxic T-Lymphocytes. Clinical Cancer Research 10:11, pages 3658-3666.
Crossref
Crossref
Francis J Giles, Julie M Vose, Kim-Anh Do, Marcella M Johnson, Taghi Manshouri, Gregory Bociek, Philip J Bierman, Susan M O’Brien, Hagop M Kantarjian, James O Armitage & Maher Albitar. (2004) Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin’s lymphoma or Hodgkin’s lymphoma. Leukemia Research 28:6, pages 595-604.
Crossref
Crossref
Nils Glenjen, Randi Hovland, Line Wergeland, Øystein Wendelbo, Peter Ernst & Øystein Bruserud. (2003) The angioregulatory phenotype of native human acute myelogenous leukemia cells: influence of karyotype, Flt3 abnormalities and differentiation status. European Journal of Haematology 71:3, pages 163-173.
Crossref
Crossref
Renchi Yang & Zhong Chao Han. (2002) Angiogenesis in Hematologic Malignancies and Its Clinical Implications. International Journal of Hematology 75:3, pages 246-256.
Crossref
Crossref
Regina M Day, Lilian Soon, Diane Breckenridge, Benjamin Bridges, Bharvin K R Patel, Ling Mei Wang, Seth J Corey & Donald P Bottaro. (2002) Mitogenic synergy through multilevel convergence of hepatocyte growth factor and interleukin-4 signaling pathways. Oncogene 21:14, pages 2201-2211.
Crossref
Crossref
Francis J. Giles. (2001) The Vascular Endothelial Growth Factor (VEGF) Signaling Pathway: A Therapeutic Target in Patients with Hematologic Malignancies. The Oncologist 6:S5, pages 32-39.
Crossref
Crossref
S Verstovsek, H Kantarjian, E Estey, A Aguayo, FJ Giles, T Manshouri, C Koller, Z Estrov, E Freireich, M Keating & M Albitar. (2001) Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia 15:8, pages 1165-1170.
Crossref
Crossref
Luciana TeofiliAnna Laura Di FeboFrancesco PiercontiNicola MaggianoMaurizio BendandiSergio RutellaAntonella CingolaniNicola Di RenzoPellegrino MustoStefano PileriGiuseppe LeoneLuigi Maria Larocca. (2001) Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood 97:4, pages 1063-1069.
Crossref
Crossref
Nelida N. Sjak-Shie, Robert A. Vescio & James R. Berenson. (2000) Recent advances in multiple myeloma. Current Opinion in Hematology 7:4, pages 241-246.
Crossref
Crossref
K. L. Talks & A. L. Harris. (2001) Current Status Of Antiangiogenic Factors. British Journal of Haematology 109:3, pages 477-489.
Crossref
Crossref